Biofrontera Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BIOFRONTERA, and what generic alternatives to BIOFRONTERA drugs are available?
BIOFRONTERA has two approved drugs.
There are two US patents protecting BIOFRONTERA drugs.
There are twenty-six patent family members on BIOFRONTERA drugs in eighteen countries and eleven supplementary protection certificates in seven countries.
Summary for Biofrontera
International Patents: | 26 |
US Patents: | 2 |
Tradenames: | 2 |
Ingredients: | 2 |
NDAs: | 2 |
PTAB Cases with Biofrontera as petitioner: | See PTAB cases with Biofrontera as petitioner |
Drugs and US Patents for Biofrontera
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Biofrontera | AKTIPAK | benzoyl peroxide; erythromycin | GEL;TOPICAL | 050769-001 | Nov 27, 2000 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | |||||
Biofrontera | AMELUZ | aminolevulinic acid hydrochloride | GEL;TOPICAL | 208081-001 | May 10, 2016 | RX | Yes | Yes | 11,540,981 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
Biofrontera | AMELUZ | aminolevulinic acid hydrochloride | GEL;TOPICAL | 208081-001 | May 10, 2016 | RX | Yes | Yes | 11,235,169 | ⤷ Subscribe | ⤷ Subscribe | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Biofrontera
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Biofrontera | AMELUZ | aminolevulinic acid hydrochloride | GEL;TOPICAL | 208081-001 | May 10, 2016 | 6,559,183 | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Biofrontera Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Canada | 2670715 | ⤷ Subscribe |
Mexico | 2009006088 | ⤷ Subscribe |
South Korea | 20230088755 | ⤷ Subscribe |
Uruguay | 30833 | ⤷ Subscribe |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Biofrontera Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1586316 | 122011100019 | Germany | ⤷ Subscribe | PRODUCT NAME: BROMFENAC (2-AMINO-3-(4-BROMOBENZOYL)PHENYLESSIGSAEURE); REGISTRATION NO/DATE: EU/1/11/692/001 20110518 |
1458369 | C01458369/01 | Switzerland | ⤷ Subscribe | PRODUCT NAME: ADAPALENUM + BENZOYLIS PEROXIDUM; REGISTRATION NUMBER/DATE: SWISSMEDIC 58460 19.05.2009 |
0591275 | SPC/GB05/030 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: NITISINONE (2-(2-NITRO-4-TRIFLUOROMETHYLBENZOYL)-1,3-CYCLOHEXANEDIONE) OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/04/303/001 20050221; UK EU/1/04/303/002 20050221; UK EU/1/04/303/003 20050221 |
1586316 | SPC/GB11/054 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: BROMFENAC 2-AMINO-3-(4-BROMOBENZOYL)PHENYLACETIC ACID OR A PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF OR A HYDRATE THEREOF; REGISTERED: UK EU/1/11/692/001 20110523 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.